Organ‐on‐a‐Chip: A Preclinical Microfluidic Platform for the Progress of Nanomedicine
Орган-на-чипе: доклиническая микрофлюидная платформа для развития наномедицины
2020-11-25
SCID: 54.1/kdbhe95h
Discuss with AI
microfluidic platformsnanomaterial biotoxicitynanomedicineorgan-on-a-chippreclinical validation
Figures from the paper
Abstract (AI)
Despite the progress achieved in nanomedicine during the last decade, the translation of new nanotechnology-based therapeutic systems into clinical applications has been slow, especially due to the lack of robust preclinical tissue culture platforms able to mimic the in vivo conditions found in the human body and to predict the performance and biotoxicity of the developed nanomaterials. Organ-on-a-chip (OoC) platforms are novel microfluidic tools that mimic complex human organ functions at the microscale level. These integrated microfluidic networks, with 3D tissue engineered models, have been shown high potential to reduce the discrepancies between the results derived from preclinical and clinical trials. However, there are many challenges that still need to be addressed, such as the integration of biosensor modules for long-time monitoring of different physicochemical and biochemical parameters. In this review, recent advances on OoC platforms, particularly on the preclinical validation of nanomaterials designed for cancer, as well as the current challenges and possible future directions for an end-use perspective are discussed.
Key Findings
1
Integrating biosensors for long-term monitoring of physicochemical and biochemical parameters remains a major challenge, with further development needed for end-use applications.
2
Nanomedicine translation remains slow partly because conventional preclinical tissue-culture platforms inadequately reproduce human in vivo conditions and predict nanomaterial performance and biotoxicity.
3
OoC systems show potential to reduce discrepancies between preclinical and clinical trial results for nanomedicine evaluation.
4
Organ-on-a-chip platforms combine microfluidic networks with three-dimensional tissue-engineered models to mimic complex human organ functions at microscale.
5
Recent advances include preclinical validation of cancer-targeted nanomaterials using OoC platforms.
Research Object
Organ-on-a-chip (OoC) microfluidic platforms incorporating 3D tissue-engineered human organ models
Research Subject
Preclinical validation of nanomaterials—especially cancer nanomedicines—including their in vivo-mimetic performance and biotoxicity, and the challenges of long-term physicochemical and biochemical monitoring
Publication Details
Publication Date
2020-11-25
Journal
Publisher
ISSN
Cited by
131
Access Type
Author Information
Download PDF
Subscribe to digest